MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

Leukemia

Volumn 28, Issue 10, 2014, Pages 2104-2106

  Fernandez Rodriguez C ^a,b   Bellosillo, B ^a,c   Garcia Garcia M ^a   Sanchez Gonzalez B ^a   Gimeno, E ^a   Vela, M C ^a   Serrano, S ^a   Besses, C ^a   Salar, A ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; MYELOID DIFFERENTIATION FACTOR 88; PREDNISONE; RITUXIMAB; VINCRISTINE; MYD88 PROTEIN, HUMAN;

ADULT; BRAIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; DNA EXTRACTION; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENETIC ALGORITHM; GENETIC REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LETTER; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; AGED; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84921738342     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.184     Document Type: Letter

References (15)

1. Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511
2. Ngo V, Ryan M, Schmitz R, Jhavar S, Xiao W, Lim K et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119
3. Jiménez C, Sebastián M, Chillón M, Giraldo P, Mariano J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenströ m's macroglobulinemia. Leukemia 2013; 27: 1722-1728
4. Krol ADG, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003; 14: 131-139
5. Choi J-W, Kim Y, Lee J-H, Kim Y-S. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 2013; 44: 1375-1381
6. Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203-5211
7. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 2013; 3: e139
8. Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2014; 53: 144-153
9. Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJM, MECM Oud, Noorduyn LA et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2013; 28: 719-720
10. Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2012; 132: 2118-2120
11. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282
12. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-243
13. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 2013; 122: 1222-1232
14. Treon S, Tripsas C, Yang G, Cao Y, Xu L, Hunter Z et al. A prospective, multicentre, phase II study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenstrom's macroglobulinemia. Hematol Oncol 2013; 31(Suppl 1): 119 (abstract 067)
15. Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood (ASH Annu Meet Abstr) 2012; 120: abstract 686.